Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03620357 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
A NA study, sponsored by DexCom.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT03620357 is a NA study that has completed, run by DexCom. The registered enrollment target is 72 participants.
The verdict
NCT03620357, a NA study, has completed, sponsored by DexCom.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous glucose monitoring (RT-CGM) and targeted learning modules versus self monitored blood glucose (SMBG) testing.
Interventions
- DEVICE CGM
- DEVICE SMBG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2020-11-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03620357
The ClinicalTrials.gov registry entry for NCT03620357 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DexCom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CGM is the first listed.
NCT03620357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03620357 about?
NCT03620357 is a clinical study titled "Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)". A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous glucose monitoring (RT-CGM) and targeted learning modules versus self moni...
What is the current status of trial NCT03620357?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2018-09-05. Estimated completion is 2020-11-04.
What interventions are being tested in trial NCT03620357?
The interventions under investigation include: CGM (DEVICE), SMBG (DEVICE).
Who is sponsoring clinical trial NCT03620357?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.